Clinical Trials · NCT00593853
Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- University Health Network, Toronto
- Enrollment
- 33
- Start date
- Jan 2008
- Locations
- 1 site, Canada
- Primary endpoint
- To assess the ability of methylphenidate 5 mg BID (10 mg daily) to reduce LHRH-agonist-related fatigue in prostate cancer patients as measured by the Functional Assessment of Cancer Therapy Fatigue subscale (FACT-F).